Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 49, Issue 2, Pages 153-163Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1040-8428(03)00120-3
Keywords
oral idarubicin; elderly breast cancer patients; oral anthracyclines
Categories
Ask authors/readers for more resources
Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available